Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

2007 ◽  
Vol 29 (6) ◽  
pp. 687-710 ◽  
Author(s):  
Shu-Feng Zhou ◽  
Charlie Changli Xue ◽  
Xue-Qing Yu ◽  
Chunguang Li ◽  
Guangji Wang
Keyword(s):  
Cytochrome P450 ◽  
Therapeutic Drug Monitoring ◽  
Drug Interactions ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Cytochrome P450 3A4 ◽  
Important Drug

scholarly journals Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections

2012 ◽  
Vol 56 (11) ◽  
pp. 6001-6002 ◽  
Author(s):  
Natalie K. Boyd ◽  
Cindy L. Zoellner ◽  
Mark A. Swancutt ◽  
Kavita P. Bhavan
Keyword(s):  
Cytochrome P450 ◽  
Therapeutic Drug Monitoring ◽  
Drug Interactions ◽  
Drug Monitoring ◽  
Antifungal Agent ◽  
Therapeutic Drug ◽  
Content Type ◽  
Trough Concentrations

ABSTRACTVoriconazole is the preferred antifungal agent forAspergillusinfections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole “boosting” effect of omeprazole to achieve target concentrations for the treatment ofAspergillusin a patient who had persistently subtherapeutic trough concentrations.

scholarly journals The role of therapeutic drug monitoring in treatment of HIV infection

2001 ◽  
Vol 52 (S1) ◽  
pp. 89-96
Author(s):  
David J. Back ◽  
Saye H. Khoo ◽  
Sara E. Gibbons ◽  
Concepta Merry
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Hiv Infection ◽  
Drug Monitoring ◽  
Therapeutic Drug

scholarly journals Role of Therapeutic Drug Monitoring and Challenges in the Management of Infantile Chronic Myeloid Leukemia

2021 ◽  
Vol 18 (2) ◽  
Author(s):  
Sneha Tandon ◽  
Raviraj Deshpande ◽  
Gaurav Narula ◽  
Maya Prasad ◽  
Amey Paradkar ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Myeloid Leukemia ◽  
Therapeutic Drug

scholarly journals Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?

2017 ◽  
Vol 51 (06) ◽  
pp. 270-271 ◽  
Author(s):  
Sara Baldelli ◽  
Emilio Clementi ◽  
Dario Cattaneo
Keyword(s):  
Clinical Practice ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Atypical Antipsychotics ◽  
Therapeutic Targets ◽  
Therapeutic Drug ◽  
Consensus Guidelines ◽  
Long Acting

AbstractThe updated AGNP Consensus Guidelines for Therapeutic Drug Monitoring (TDM) in Neuropsychopharmacology recently published in the journal have reinforced the key role of TDM to individualize psychoparmacological therapies in clinical practice. However, we believe, that these guidelines have missed the important opportunity to face with, and to provide useful information on, the emerging issue of long-acting injectable formulations of atypical antipsychotics. Specific therapeutic ranges also for these formulations should be included in the next AGNP guidelines.

Neural and Kernal Methods for Therapeutic Drug Monitoring

2011 ◽  
pp. 238-261 ◽  
Author(s):  
G. Camps-Valls ◽  
J. D. Martin-Guerrero
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Substantial Improvement ◽  
Physical Models ◽  
Therapeutic Drug ◽  
Optimal Dosage ◽  
Blood Concentrations ◽  
Clinical Problems

Recently, important advances in dosage formulations, therapeutic drug monitoring (TDM), and the emerging role of combined therapies have resulted in a substantial improvement in patients’ quality of life. Nevertheless, the increasing amounts of collected data and the non-linear nature of the underlying pharmacokinetic processes justify the development of mathematical models capable of predicting concentrations of a given administered drug and then adjusting the optimal dosage. Physical models of drug absorption and distribution and Bayesian forecasting have been used to predict blood concentrations, but their performance is not optimal and has given rise to the appearance of neural and kernel methods that could improve it. In this chapter, we present a complete review of neural and kernel models for TDM. All presented methods are theoretically motivated, and illustrative examples in real clinical problems are included.

Pharmacokinetic Properties of New Antiepileptic Drugs

2005 ◽  
Vol 18 (6) ◽  
pp. 444-460 ◽  
Author(s):  
Michele Y. Splinter
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Interactions ◽  
Antiepileptic Drugs ◽  
Drug Monitoring ◽  
The United States ◽  
Therapeutic Drug ◽  
Kinetic Properties ◽  
New Antiepileptic Drugs ◽  
Drug Concentrations ◽  
Pharmacokinetic Properties

Eight new antiepileptic drugs (AEDs) have been approved for use within the United States within the past decade. They are felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, and zonisamide. These afford clinicians with more options to increase efficacy and tolerability in the treatment of patients with epilepsy. Pharmacokinetic properties and drug interactions with other AEDs and other medications taken for comorbidities are individually discussed for each of these new agents. Drug concentrations are not routinely monitored for these newer agents, and there have been few studies designed to investigate their concentration-effect relationships. For most of these medications, the concentrations observed in responders and nonresponders overlap considerably and levels associated with efficacy are often associated with adverse events, complicating the definition of target ranges. Also, epilepsy manifests itself sporadically causing difficulty in clinically monitoring efficacy of medications. Therapeutic drug monitoring provides for the individualization of treatment for these agents, which is important because they demonstrate significant variability in inter- and intraindividual pharmaco-kinetic properties. Therapeutic drug monitoring also allows for identification of noncompliance, drug interactions, and toxicity. Current knowledge of the relationships between efficacy, toxicity, and drug concentrations is discussed.

scholarly journals Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples

Bioanalysis ◽  
2015 ◽  
Vol 7 (4) ◽  
pp. 481-495 ◽  
Author(s):  
Susan Hofman ◽  
Mathieu S Bolhuis ◽  
Remco A Koster ◽  
Onno W Akkerman ◽  
Sander van Assen ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Dried Blood Spot ◽  
Therapeutic Drug ◽  
Pulmonary Infections ◽  
Blood Spot
Sign in / Sign up

Export Citation Format

Share Document